(Q36689156)

15 August 2017

1 reference

title

Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia (English)

1 reference

ORCID Public Data File 2021

15 August 2017

0 references

Giovanni Del Poeta

1 reference

Pasquale Niscola

object named as

Pasquale Niscola

1 reference

15 August 2017

author name string

Maria Ilaria Del Principe

1 reference

15 August 2017

Francesco Buccisano

1 reference

15 August 2017

Luca Maurillo

1 reference

15 August 2017

Adriano Venditti

1 reference

15 August 2017

Sergio Amadori

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

1787-1800

1 reference

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Analysis of somatic mutation in five B cell subsets of human tonsil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Classical and new prognostic factors in chronic lymphocytic leukemia: where to now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Clinical significance of CD38 expression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Campath-1H monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1787

10.1586/14737140.6.12.1787

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference